ES2194412T3 - Uso de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de vasculitis resistente al tratamiento. - Google Patents

Uso de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de vasculitis resistente al tratamiento.

Info

Publication number
ES2194412T3
ES2194412T3 ES99122051T ES99122051T ES2194412T3 ES 2194412 T3 ES2194412 T3 ES 2194412T3 ES 99122051 T ES99122051 T ES 99122051T ES 99122051 T ES99122051 T ES 99122051T ES 2194412 T3 ES2194412 T3 ES 2194412T3
Authority
ES
Spain
Prior art keywords
treatment
group
hidantoine
vasculitis
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99122051T
Other languages
English (en)
Inventor
Mitsuru Naiki
Takumi Numazawa
Tomoyuki Okada
Kazuharu Ienaga
Kazuyoshi Sawada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2194412T3 publication Critical patent/ES2194412T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de un derivado de la hidantoína representado por la fórmula (I) o una sal de la misma aceptable desde un punto de vista farmacéutico **FORMULA** en la que cada uno de R1 y R2, que pueden ser iguales o diferentes, representan hidrógeno, un grupo alquilo o un grupo cicloalquilo; y cada uno de X e Y, que pueden ser iguales o diferentes, representan hidrógeno, grupo hidroxilo, un grupo alquilo o un grupo alcoxi, o X e Y juntos representan un grupo oxo, como un ingrediente eficaz en la fabricación de una composición farmacéutica eficaz en la terapia y prevención de la periarteritis nodosa (PN), la granulomatosis de Wegener (WG), la artritis reumatoide maligna (MRA), la enfermedad de Burger y el síndrome de anticuerpos anti-fosfolípidos.
ES99122051T 1998-11-16 1999-11-16 Uso de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de vasculitis resistente al tratamiento. Expired - Lifetime ES2194412T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32479098 1998-11-16

Publications (1)

Publication Number Publication Date
ES2194412T3 true ES2194412T3 (es) 2003-11-16

Family

ID=18169718

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99122051T Expired - Lifetime ES2194412T3 (es) 1998-11-16 1999-11-16 Uso de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de vasculitis resistente al tratamiento.

Country Status (11)

Country Link
US (1) US6251929B1 (es)
EP (1) EP1018339B1 (es)
JP (1) JP4451521B2 (es)
KR (1) KR100648062B1 (es)
CN (1) CN1143674C (es)
AT (1) ATE238789T1 (es)
AU (1) AU754989B2 (es)
CA (1) CA2289880C (es)
DE (1) DE69907387T2 (es)
ES (1) ES2194412T3 (es)
TW (1) TW528595B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4711523B2 (ja) * 2001-02-13 2011-06-29 日本臓器製薬株式会社 低アルブミン血症改善剤
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US20060241163A1 (en) * 2005-04-20 2006-10-26 Kaoru Okamoto Optically active (S)-hydantoin derivative
US20060241162A1 (en) * 2005-04-20 2006-10-26 Kaoru Okamoto Optically active (R)-hydantoin derivative
TWI483729B (zh) 2010-03-11 2015-05-11 Nippon Zoki Pharmaceutical Co 慢性前列腺炎、間質性膀胱炎及／或排尿障礙之改善或治療劑
KR101894754B1 (ko) 2010-10-14 2018-09-04 니폰 조키 세야쿠 가부시키가이샤 연골세포의 콜라겐 및 프로테오글리칸의 합성 촉진 방법
SG11201704764PA (en) 2014-12-11 2017-07-28 Harvard College Inhibitors of cellular necrosis and related methods
WO2018230537A1 (ja) 2017-06-13 2018-12-20 国立研究開発法人国立がん研究センター 発がん抑制剤

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099007A (en) 1969-04-02 1978-07-04 Hoechst Aktiengesellschaft N,n-substituted 2,4,5-triketoimidazolidines and a process for their preparation
CH563711A5 (en) 1972-03-03 1975-07-15 Ciba Geigy Ag Agents for regulating plant metabolism - contg. imidazolidine-2,4,5-trione-3-carboxylic acid derivs.
IL39042A (en) 1971-03-26 1976-04-30 Ciba Geigy Ag 2,4,5-trioxoimidazolidine-1-carboxylic acid derivatives,their preparation and their use for the control of plant metabolism
US3818031A (en) 1971-03-26 1974-06-18 Ciba Geigy Corp Imidazolidinetrionecarboxylic acid derivatives
DE2612926A1 (de) 1976-03-26 1977-10-06 Boehringer Mannheim Gmbh Neue acyl-derivate der 6-(alpha- amino-phenylacetamido)-penicillansaeure
JPS554305A (en) 1978-06-13 1980-01-12 Nippon Zoki Pharmaceut Co Ltd Remedy for disease caused by stress and its preparation
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
JPH0686436B2 (ja) 1984-11-15 1994-11-02 日本臓器製薬株式会社 新規ヒダントイン誘導体及び該化合物を含有する医薬組成物
AU578068B2 (en) 1984-03-08 1988-10-13 Nippon Zoki Pharmaceutical Co., Ltd. Hydantoin derivatives and pharmaceutical compositions containing them
BE899531A (fr) 1984-04-27 1984-08-16 Wallone Region Derives sulfures de l'hydantoine et compositions pharmaceutiques les contenant.
US4656034A (en) 1985-05-20 1987-04-07 Survival Technology, Inc. Absorption enhancing agents
US4832682A (en) 1984-08-08 1989-05-23 Survival Technology, Inc. Injection method and apparatus with electrical blood absorbing stimulation
US5078680A (en) 1984-08-08 1992-01-07 Survival Technology, Inc. Automatic injector for emergency treatment
US4661469A (en) 1984-08-08 1987-04-28 Survival Technology, Inc. t-PA composition capable of being absorbed into the blood stream and method of administration
CA1265052A (en) 1984-08-08 1990-01-30 Stanley J. Sarnoff Absorption enhancing agents
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US5340829A (en) 1984-11-20 1994-08-23 Washington Research Foundation Immunoregulatory agents
ATE50248T1 (de) 1985-02-06 1990-02-15 Nippon Zoki Pharmaceutical Co Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung.
JPH0764729B2 (ja) 1985-02-06 1995-07-12 日本臓器製薬株式会社 イミダゾリジントリオン誘導体を含有する医薬組成物
JP2567593B2 (ja) 1986-12-29 1996-12-25 日本臓器製薬株式会社 イミダゾリジントリオン誘導体及び該化合物を有効成分として含有するアレルギ−性疾患治療剤
JPS6456614A (en) 1987-08-27 1989-03-03 Ono Pharmaceutical Co Maillard reaction inhibitor
JP2673381B2 (ja) * 1990-02-23 1997-11-05 持田製薬 株式会社 糖尿病前症治療剤および／または脂質低下剤
JPH01156965A (ja) 1987-09-29 1989-06-20 Taiho Yakuhin Kogyo Kk チオヒダントイン化合物
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
JP2544183B2 (ja) 1988-07-29 1996-10-16 日本臓器製薬株式会社 新規パラバン酸誘導体及び該化合物を有効成分として含有する医薬組成物
JP2817219B2 (ja) 1988-09-08 1998-10-30 武田薬品工業株式会社 カルバジン酸誘導体、その製造法及び製剤
JPH02225485A (ja) 1989-02-27 1990-09-07 Taiho Yakuhin Kogyo Kk チエノピリミジン―３―酢酸誘導体
CA2011899A1 (en) 1989-03-13 1990-09-13 Masaaki Toda Benzopyran derivatives
JP2678499B2 (ja) 1989-08-09 1997-11-17 日本臓器製薬 株式会社 尿毒症毒素低下剤
JPH0667827A (ja) 1992-08-18 1994-03-11 Nec Software Ltd データ表示制御装置
JP3267698B2 (ja) 1992-10-27 2002-03-18 株式会社三和化学研究所 ヒダントイン誘導体及びその塩並びにこれらを有効成分とするメイラード反応阻害剤
JPH06305964A (ja) 1993-02-26 1994-11-01 Otsuka Pharmaceut Co Ltd メイラード反応阻害剤
EP0638075B1 (en) 1993-02-26 2002-01-16 Otsuka Pharmaceutical Co., Ltd. Thiazole or imidazole derivatives as maillard reaction inhibitors
AU3086095A (en) 1994-07-29 1996-03-04 Suntory Limited Imidazolidine derivative and use thereof
JPH08157473A (ja) 1994-10-06 1996-06-18 Nissan Chem Ind Ltd ピラゾール系チアゾリジン類
US5681843A (en) 1994-12-20 1997-10-28 Nippon Zoki Pharmaceutical Co., Ltd. Parabanic acid derivatives
US5912261A (en) 1994-12-20 1999-06-15 Nippon Zoki Pharmaceutical Co., Ltd. Carboxyalkyl heterocyclic derivatives
US6197806B1 (en) 1995-12-20 2001-03-06 Nippon Zoki Pharmaceutical Co., Ltd. Eliminating agent for activated oxygen and free radicals
JPH10182460A (ja) 1996-12-27 1998-07-07 Nippon Zoki Pharmaceut Co Ltd ３−デオキシグルコソン生成阻害剤

Also Published As

Publication number Publication date
KR100648062B1 (ko) 2006-11-23
CA2289880A1 (en) 2000-05-16
JP2000212083A (ja) 2000-08-02
AU5828399A (en) 2000-05-18
CA2289880C (en) 2009-01-20
US6251929B1 (en) 2001-06-26
DE69907387T2 (de) 2004-02-12
EP1018339A1 (en) 2000-07-12
EP1018339B1 (en) 2003-05-02
ATE238789T1 (de) 2003-05-15
DE69907387D1 (de) 2003-06-05
CN1253775A (zh) 2000-05-24
JP4451521B2 (ja) 2010-04-14
TW528595B (en) 2003-04-21
AU754989B2 (en) 2002-11-28
KR20000035443A (ko) 2000-06-26
CN1143674C (zh) 2004-03-31

Similar Documents

Publication Publication Date Title
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
UY25225A1 (es) Derivados de pleuromutilina utiles como agentes antimicrobianos
ES2078798T3 (es) Derivados de quinazolina.
AR011134A1 (es) Derivados de imidazo piridina substituidos para la inhibicion de la secrecion de acido gastrico; una sal del mismo, procedimiento para su preparacion, formulacion farmaceutica que los contiene y el uso de dicho compuesto para la manufactura de un medicamento
SV1999000049A (es) Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DK1140745T3 (da) Colchinolderivater som vaskulært skadelige midler
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
UY27592A1 (es) Nuevo uso
FI922806A0 (fi) Substituerade 4-fenyl-4 -piperidinkarboxamider med baode lokalbedoevande och smaertstillande effekt samt foerfaranden foer deras framstaellning.
LU91178I2 (fr) Emtricitabine / Tenofovir Disoproxil et ses dérivés pharmaceutiquement acceptables (TRUVADA).
ES2123546T3 (es) Uso de derivados de 1-(aminoalquil)-3-quinoxalina-2-ona para la preparacion de composiciones neuroprotectoras.
NO964121D0 (no) Pyrimidin- eller triazin-karboksylsyrederivater for anvendelse som legemidler
BR0113590A (pt) 7-oxo-piridopirimidinas
ES2194412T3 (es) Uso de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de vasculitis resistente al tratamiento.
ATE108437T1 (de) Substituierte diaminophthalimide und analoga.
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
BR0017120A (pt) Composição farmacêutica
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
DK0609336T3 (da) Anvendelse af prostacyclin-derivater til forebyggelse eller behandling af lidelser i mikrocirkulationssystemet ved administ
AR029666A1 (es) Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina
FR2804958B1 (fr) Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
BR9306870A (pt) Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol